Bio-Rad Introduces First Droplet Digital™ PCR–Based Assays to Quickly Quantify CRISPR Efficiency

Today announced the launch of ddPCR Genome Edit Detection Assays

Bio-Rad
Jul 6, 2017
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), today announced the launch of ddPCR™ Genome Edit Detection Assays, the first tests to characterize edits generated by CRISPR-Cas9 or other genome editing tools using Bio-Rad’s Droplet Digital PCR (ddPCR) technology. Users can specify their sequences and order assays through Bio-Rad’s Digital Assay Site.
 
Successful genome editing is a rare outcome that depends substantially on experimental conditions including type of cells used, transfection method, target sequence, and many other factors. Editing stem cell genomes, for example, typically succeeds in less than 5% of cells.
 
Current methods for assessing genome edit efficiency, including next-generation sequencing (NGS) and high resolution melt analysis, present drawbacks in cost, time, simplicity, and sensitivity. With NGS, for example, turnaround time is often several weeks and analysis is complex and costly, making NGS less than optimal for routine screening. Additionally, maximum sensitivity requires researchers to sequence the...

 

Interested in reading more?

Bio-Rad Introduces First Droplet Digital™ PCR–Based Assays to Quickly Quantify CRISPR Efficiency

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?